Ranibizumab for idiopathic retinal vasculitis, aneurysms, and neuroretinitis: Favorable results

European Journal of Ophthalmology

Volumn 20, Issue 4, 2010, Pages 792-794

  Karagiannis, Dimitrios ^a   Soumplis, Vasileios ^a   Georgalas, Mas ^b   Kandarakis, Artemios ^a  

^a Athens Eye Hospital   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Adjunctive treatment; IRVAN; Ranibizumab

Indexed keywords

RANIBIZUMAB;

ADULT; ARTICLE; CASE REPORT; EYE EXAMINATION; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; IDIOPATHIC RETINAL VASCULITIS ANEURYSM AND NEURORETINITIS SYNDROME; LASER COAGULATION; OPTIC NERVE DISEASE; PRIORITY JOURNAL; REMISSION; RETINA DISEASE; VISUAL ACUITY; VITRECTOMY;

EID: 77955790583     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067211002000425     Document Type: Article

References (7)

1. Owens SL, Gregor ZJ. Vanishing retinal aneurysms: a case report. Br J Ophthalmol 1992; 76: 637-8.
2. Chang TS, Aylward GW, Davis JL, et al. Idiopathic retinal vasculitis, aneurysms, and neuro-retinitis. Retinal Vasculitis Study. Ophthalmology 1995; 102: 1089-97.
3. Jardeleza MS, Miller JW. Review of anti-VEGF therapy in proliferative diabetic retinopathy. Semin Ophthalmol 2009; 24: 87-92.
4. Samuel MA, Equi RA, Chang TS, et al. Idiopathic retinitis, vasculitis, aneurysms, and neuroretinitis (IRVAN): new observations and a proposed staging system. Ophthalmology 2007; 114: 1526-9.
5. Cohen SY. Anti-VEGF drugs as the 2009 first-line therapy for choroidal neovascularization in pathologic myopia. Retina 2009; 29: 1062-6.
6. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-31.
7. Ciulla TA, Rosenfeld PJ. Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration. Curr Opin Ophthalmol 2009; 20: 166-74.